What this means
Researchers plan to test two drugs, rapamycin and everolimus, in healthy older adults to find a safe dose and timing. This trial is still recruiting, so it does not yet show whether the drugs work.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65–90
- Where
- 1 site, including Texas
The science
- Registered title
- RESTOR: PK/PD mTORi Inhibition in Older Adults
- Trial ID
- NCT06658093 ↗
- Phase
- EARLY PHASE 1
- Study type
- interventional
- Conditions
- Aging
- What is tested
- Rapamycin, Everolimus, Placebo
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Ages
- 65 Years to 90 Years
- Dates
- First posted Oct 26, 2024 · updated Jun 1, 2026
Registry summary
As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the aging process, leading to a longer, healthier life. This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons. The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.
Sites (1)
- The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States